Disease States: Schizophrenia


ASCP 2024

Measurement of positive and negative symptoms through speech analysis from PANSS interview recordings in individuals with schizophrenia

ASCP 2024

Assessing Participant Experience with KarXT Treatment Using In-Trial Qualitative Interviews: Initial Findings from a Long-Term Phase 3 Trial in Schizophrenia

ASCP 2024

Low Long-Term Risk of EPS With Muscarinic Agonist KarXT (Xanomeline and Trospium Chloride)

ASCP 2024

KarXT (Xanomeline and Trospium) for the Treatment of Schizophrenia: Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed

ASCP 2024

Response to KarXT in Short-Term Placebo-Controlled Trials in Schizophrenia

ASCP 2024

Characterizing the Safety Profile of KarXT Relative to Anticipated D2 Dopamine–Based Antipsychotic Medications in FAERS

SOBP 2024

Understanding the Role of Muscarinic M1 and M4 Receptors in Neural Circuits That Modulate Negative Symptoms of Schizophrenia

ISPOR 2024

Comparative Efficacy, Safety, and Tolerability of KarXT versus Aripiprazole and Cariprazine for the Acute Treatment of Adults with Schizophrenia – A Network Meta-Analysis

SIRS 2024

Long-Term Metabolic Outcomes Associated With KarXT (Xanomeline and Trospium): Interim Results From Pooled, Long-Term Safety Studies EMERGENT-4 and EMERGENT-5